AI Article Synopsis
- The study aimed to compare the effectiveness of using Contigen with Durasphere versus Contigen alone for treating stress urinary incontinence (SUI) with intrinsic sphincter deficiency (ISD).
- At 2 weeks post-treatment, the combined injection group had better short-term success rates (72.7% cured) compared to the Contigen-only group (39.2%), but this improvement was not significant at 6 months (33.3% vs. 29.4%).
- The combined injection group experienced higher rates of urinary retention, but there was no significant difference in the need for subsequent incontinence surgeries between the two groups.
Article Abstract
The purpose of this study was to compare Contigen combined with Durasphere to Contigen injections alone for the treatment of stress urinary incontinence (SUI) with intrinsic sphincter deficiency (ISD). Subjective and objective incontinence outcomes were compared at 2 weeks and 6 months. We compared rates of urinary retention and future incontinence surgery between groups. Thirty-three women underwent combined injections, and 51 underwent Contigen injections. Two weeks postoperatively, more women in the combined group were cured (72.7 vs. 39.2%, P = 0.003), but this difference diminished at 6 months (33.3 vs. 29.4%, P = 0.70). Retention was more common in the combined group (P = 0.002, odds ratio [OR] = 0.062 [95% confidence interval (CI) = 0.007, 0.52]). Twenty-three women in the Contigen and ten in the combined group underwent subsequent incontinence surgery (P = 0.17, OR = 2.03 [95% CI = 0.80, 5.1]). Combining Contigen and Durasphere injections to treat SUI with ISD does not improve outcomes compared to Contigen injections alone.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00192-007-0493-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Urethral bulking agents for the treatment of stress urinary incontinence in women: A systematic review.
Neurourol Urodyn
August 2021
Department of Urology, Western Health, St Albans, Victoria, Australia.
Aims: To perform a systematic review to assess and compare the efficacy and safety of all urethral bulking agents (UBAs) available for the treatment of stress urinary incontinence (SUI) in women.
Methods: This systematic review was conducted in accordance with the PRISMA guideline. A systematic search was conducted using the Ovid Medline, Embase and PubMed databases.
Regenerative medicine and injection therapies in stress urinary incontinence.
Nat Rev Urol
March 2020
Royal Hallamshire Hospital, Glossop Road, Sheffield, UK.
Stress urinary incontinence (SUI) is a common and bothersome condition. Anti-incontinence surgery has high cure rates, but concerns about mesh tapes have resulted in the resurgence of surgical procedures that involve increased abdominopelvic dissection and morbidity. Injection therapy with urethral bulking agents or stem cell formulations have been developed as minimally invasive alternatives.
View Article and Find Full Text PDFPatient Characteristics that May Influence the Effect of Urethral Injection Therapy for Female Stress Urinary Incontinence.
J Urol
July 2019
Department of Obstetrics and Gynecology, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen , Denmark.
Purpose: Urethral injection therapy is a well-known treatment of female stress urinary incontinence but to our knowledge the optimal group of recipients has not been established. In this study we examined which patient characteristics are associated with success after urethral injection therapy.
Materials And Methods: This study is a post hoc analysis of a previously published, randomized, 33-center study of the hydrogel bulking agent Bulkamid® vs the collagen gel Contigen®.
Retrospective analysis after endoscopic urethral injections of glutaraldehyde-cross-linked-collagen or dextranomer/hyaluronic acid copolymer in bitches with urinary incontinence.
J Small Anim Pract
February 2019
EVIDENSIA Tierärztliche Klinik für Kleintiere Norderstedt GmbH, 22850 Norderstedt, Germany.
Objectives: To evaluate the outcome of endoscopic injection of two different bulking agents, glutaraldehyde cross-linked collagen and dextranomer/hyaluronic acid copolymer into the urethral submucosa in female dogs with urinary incontinence caused by urethral sphincter mechanism incompetence.
Materials And Methods: Retrospective review of records and follow-up communication with owners of dogs that received an endoscopically guided urethral bulking procedure. In each dog, either cross-linked collagen (2007 to 2011) or dextranomer/hyaluronic acid copolymer (2012 to 2015) was used.
Urethral injection therapy for urinary incontinence in women.
Cochrane Database Syst Rev
July 2017
Department of Urology, Sunderland Royal Hospital, Kayll Road, Sunderland, Tyne & Wear, UK, SR4 7TP.
Background: Urinary incontinence imposes a significant health and economic burden to society. Periurethral or transurethral injection of bulking agents is a minimally invasive surgical procedure used as one the surgical treatments of stress urinary incontinence (SUI) in adult women.
Objectives: To assess the effects of periurethral or transurethral injection therapy on the cure or improvement of urinary incontinence in women.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!